Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.
3d
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
Arvinas (NASDAQ:ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical ...
I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results